<DOC>
	<DOCNO>NCT01370876</DOCNO>
	<brief_summary>To evaluate objective response rate oxaliplatin combine 5-FU patient recurrent metastatic head neck cancer ass safety profile treatment regimen .</brief_summary>
	<brief_title>Efficacy Safety Study Oxaliplatin/5-FU Patients With Recurrent Metastatic Head Neck Cancer</brief_title>
	<detailed_description>To evaluate objective response rate oxaliplatin combine 5-FU patient recurrent metastatic head neck cancer . To assess safety profile treatment regimen . To evaluate duration response oxaliplatin/5-FU .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients must histologically confirm squamous cell carcinoma head neck ( SCCHN ) except nasopharyngeal cancer . Patients must recurrent metastatic disease curative surgery radiotherapy exist longer effective . Prior enter protocol treatment , 6 month interval previous systemic chemotherapy protocol treatment . The disease must measurable computed tomographic ( CT ) scan MRI ( do within 30 day study entry ) diameter target tumor least 1 cm . Patients must 20 year age 75 year age . Patients must ECOG performance status score 2 . Patient 's hematologic function , liver function renal function must meet eligibility requirement . Patients must sign informed consent . Patients known hypersensitivity history Platinum compound 5Fluorouracil . Patients brain metastasis . Patients bone metastasis . Patients pregnancy breastfeed . Patient CTC ( NCI Common Toxicity Criteria ) grade 2 peripheral neuropathy cause clinically detectable . Patients serious concomitant illness might aggravate chemotherapy condition judge physician 's discretion . Patients receive anticancer cancer drug ( ) SCCHN .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Oxaliplatin</keyword>
	<keyword>Head Neck cancer</keyword>
</DOC>